ALKERMES | ALKS - 贷款资金

金融业

USD

USD 4.39B

现金及等价物

USD 511.53M

USD 120.7M

USD 1.52B

USD 662.09M

USD 1.58B

股息收益率

0

USD -65.93M

USD 139.22M

1.8K

EPS每股收益

USD 0

股本和储备

USD 1.81B

USD 375.31M

债务利息支出

USD 25.93M

USD 8.54M

USD 1.48B

USD 7.42B

USD 501K

USD 1.81B

USD -65.93M

普通股股本

USD 167.54M

135.81

USD -61.93M

USD 496.01M

销售和管理费用

USD 196.64M

USD 298.96M

贸易债权人

USD 142.86M

应收帐款人

USD 456.48M

	贷款资金	更改		日
AbbVie	USD 64.53B		5.59B	2026-03
Acadia Pharmaceuticals	USD 0		0	2025-03
ALKERMES	USD 1.48B		7.23M	2026-06
Amgen	USD 51.86B		27M	2026-06
Biogen	USD 7.29B		1B	2026-06
BioMarin Pharmaceutical	USD 3.53B		2.1B	2026-06
Bristol-Myers Squibb	USD 42.09B		59M	2026-06
Coherus Biosciences	USD 51.08M		496K	2025-12
Eli Lilly	USD 47.86B		8.49B	2026-06
Gilead Sciences	USD 20.86B		1.27B	2026-03
Heron Therapeutics	USD 140.64M		975K	2025-12
Ionis Pharmaceuticals	USD 1.91B		6.62M	2026-06
J&J	USD 37.34B		183M	2026-06
Malin Corporation	EUR 0		0	2024-12
Merck	USD 51.08B		4.41B	2026-06
Minerva Neurosciences	USD 0		86.58M	2024-09
Nektar Therapeutics	USD 60.27M		2.89M	2026-03
Neurocrine Biosciences	USD 169.5M		500K	2023-03
Otsuka Holdings	JPY 164.66B		301M	2026-06
Ovoca Bio	EUR 0		0	2021-06
Pfizer	USD 60.5B		70M	2026-06
Regeneron Pharmaceuticals	USD 1.99B		400K	2026-06
Vertex Pharmaceuticals	USD 106.7M		4.7M	2025-12